carbon-11-methionine and Meningeal-Neoplasms

carbon-11-methionine has been researched along with Meningeal-Neoplasms* in 3 studies

Other Studies

3 other study(ies) available for carbon-11-methionine and Meningeal-Neoplasms

ArticleYear
Analysis of progression and recurrence of meningioma using (11)C-methionine PET.
    Annals of nuclear medicine, 2013, Volume: 27, Issue:8

    The recurrence rate of meningioma after surgery is high, and progression is often observed. The risk factors for recurrence and progression are not clear. We evaluated the risk factors for recurrence and progression in meningioma using (11)C-methionine (MET) positron emission tomography (PET).. Thirty-seven patients (mean follow-up, 80 months) with an intracranial meningioma were enrolled. MET PET was performed before treatment between 1995 and 2010, and patients were followed up in an out-patient clinic. Surgery was performed in 33 patients, and a wait-and-see approach was taken in four patients. We evaluated the extent of tumor resection, location, WHO grade, Ki-67 labeling index, and lesion to normal ratio (LN ratio) of MET uptake.. Six of the surgical cases had a recurrence, and two of the observation-only patients had tumor progression. A high LN ratio of MET uptake was a significant risk factor for recurrence and progression with univariate analysis. The area under the curve of receiver operating characteristic curve for the LN ratio of MET uptake was 0.754, and the optimal cutoff value was 3.18 (sensitivity 63 %, specificity 79 %). With multivariate analysis, a high LN ratio of MET uptake, non-gross total resection, and a high WHO grade were significant risk factors for progression and recurrence.. A high LN ratio of MET uptake was a risk factor for tumor progression and recurrence. The advantage of MET PET is that it is not invasive and can easily be used to evaluate the whole tumor.

    Topics: Adult; Aged; Disease Progression; Female; Humans; Male; Meningeal Neoplasms; Meningioma; Methionine; Middle Aged; Positron-Emission Tomography; Recurrence; Retrospective Studies; Risk Factors; ROC Curve; Young Adult

2013
F-18 FDG and C-11 methionine PET/CT in intracranial dural metastases.
    Clinical nuclear medicine, 2012, Volume: 37, Issue:2

    A 58-year-old woman with breast carcinoma, after mastectomy, radiotherapy, and chemotherapy, underwent a whole-body F-18 FDG PET/CT for restaging, which revealed multiple skeletal metastasis. Hypometabolism was noted in the right frontal lobe. The patient subsequently underwent a C-11 methionine brain scan, which demonstrated multiple dural-based metastatic foci confirmed on contrast-enhanced MR. FDG PET has limitations in brain tumor detection. Amino acid tracers are particularly attractive for imaging of brain tumors because of relatively high tumor to brain activity ratios.

    Topics: Brain Neoplasms; Dura Mater; Female; Fluorodeoxyglucose F18; Humans; Meningeal Neoplasms; Methionine; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed

2012
C-11 methionine and F-18 FDG uptake in a patient with meningioma and glioblastoma multiforme.
    Clinical nuclear medicine, 1996, Volume: 21, Issue:7

    Topics: Aged; Brain Neoplasms; Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glioblastoma; Humans; Male; Meningeal Neoplasms; Meningioma; Methionine; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Parietal Lobe; Tomography, Emission-Computed

1996